Briacell adds three sites to Bria-IMT phase 3 study

Dr. William Williams reports BRIACELL ADDS KEY CLINICAL SITES IN PHASE 3 METASTATIC BREAST CANCER STUDY Briacell Therapeutics Corp. has added several key large cancer centres to its continuing pivotal phase 3 clinical study (ClinicalTrials.gov as NCT06072612), notably Dartmouth Cancer Center, Cedars-Sinai Medical Center and Winship Cancer Institute of Emory University. Briacell anticipates reporting top-line data as early as the first half of 2026. The extensive national effort already includes the following noteworthy clinics: Mayo Clinic, Los Angeles Cancer Network, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer and Blood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center. Briacell's pivotal phase 3 clinical study is evaluating Briacell's lead clinical candidate, Bria-IMT, plus immune checkpoint inhibitor versus physician's choice of treatment in advanced metastatic breast cancer (MBC) (Bria-ABC). "We are encouraged by the strong engagement from major academic and leading community cancer centres, which underscores confidence in Briacell's novel technology," stated Dr. William V. Williams, Briacell's president and chief executive officer. "We expect the addition of these clinical sites will further accelerate patient enrolment in Briacell's pivotal phase 3 study of Bria-IMT regimen in MBC and support our mission to bring this therapy to patients with significant unmet medical needs." About Briacell's pivotal phase 3 clinical study of Bria-IMT combination regimen in MBC patients Briacell's pivotal phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (CPI) in metastatic breast cancer is continuing. Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combination regimen versus those treated with physician's choice as the primary end point. Positive results of the pivotal phase 3 study could result in full approval and marketing authorization for Bria-IMT in MBC patients. The Bria-IMT combination regimen has received U.S. FDA (U.S. Food and Drug Administration) fast-track designation. About Briacell Therapeutics Corp. Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. We seek Safe Harbor.